Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of YM155 in hormone refractory prostate cancer
2005-003228-20Phase 2Completed
- Sponsor
- Astellas
- Start
- Sep 2005
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sepantronium in prostate cancer (PCa), sponsored by Astellas. Primary endpoint: PSA response rate. Started Sep 2005; status: completed.
02
Drugs
sepantronium
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-003228-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003228-20.